Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …

Over the past several years, there has been a surge in blood biomarker studies examining
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …

In this issue of Molecular Psychiatry, we have multiple articles that present exciting
advances. Mitochondrial dysfunction is a topic that we are highlighting, and it is addressed …

Positron emission tomography (PET) with fluorodeoxyglucose (FDG) or florbetapir (AV45)
has been proved effective in the diagnosis of Alzheimer's disease. However, the expensive …

Amyloid-beta (Aβ) plays an important role in the pathogenesis of Alzheimer's disease.
Aberrant Aβ accumulation induces neuroinflammation, cerebrovascular alterations, and …

Neurofilament light chain, a putative measure of neuronal damage, is measurable in blood
and CSF and is predictive of cognitive function in individuals with Alzheimer's disease …

Mild cognitive impairment (MCI) is regarded as a transitional stage between normal aging
and Alzheimer's disease. Numerous voxel-based morphometry (VBM) and resting-state fMRI …

Introduction The association between cerebral amyloid‐β accumulation and downstream
CSF biomarkers is not fully understood, particularly in asymptomatic stages. Methods In 318 …

Background Neurofilament light chain protein (NfL) in cerebrospinal fluid (CSF) reflects the
severity of neurodegeneration, with its altered concentrations discovered in Parkinson's …

In vivo biomarker abnormalities provide measures to monitor therapeutic interventions
targeting amyloid-β pathology as well as its effects on downstream processes associated …